Neumora Therapeutics, Inc.
NMRA$824M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaWATERTOWN95 employees
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
May 15, 2026
TomorrowMarket Overview
Stock performance and key metrics
NMRA News
Catalyst Timeline
1 upcoming, 1 past
Phase 3Next
NMRA-335140 Phase 3 Results Expected
May 2026~EstimatedNMRA-335140332
Primary completion for NMRA-335140 trial (NCT06058013) in Major Depressive Disorder
SourceDrug Pipeline
NMRA-335140
Major Depressive Disorder
NMRA-335140 80 mg
Major Depressive Episode Associated With Bipolar II Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NMRA-335140 | Phase 3 | Major Depressive Disorder | - | - |
NMRA-335140 80 mg | Phase 2 | Major Depressive Episode Associated With Bipolar II Disorder | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply